- Home
- LGO vs CHRS Comparison
LGO vs CHRS Comparison
Compare LGO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGO
- CHRS
- Stock Information
- Founded
- LGO 1988
- CHRS 2010
- Country
- LGO Canada
- CHRS United States
- Employees
- LGO N/A
- CHRS N/A
- Industry
- LGO
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LGO
- CHRS Health Care
- Exchange
- LGO Nasdaq
- CHRS Nasdaq
- Market Cap
- LGO 131.3M
- CHRS 156.0M
- IPO Year
- LGO 2007
- CHRS 2014
- Fundamental
- Price
- LGO $1.61
- CHRS $1.02
- Analyst Decision
- LGO Strong Buy
- CHRS Buy
- Analyst Count
- LGO 1
- CHRS 6
- Target Price
- LGO $4.40
- CHRS $7.10
- AVG Volume (30 Days)
- LGO 89.5K
- CHRS 1.8M
- Earning Date
- LGO 11-06-2024
- CHRS 11-04-2024
- Dividend Yield
- LGO N/A
- CHRS N/A
- EPS Growth
- LGO N/A
- CHRS N/A
- EPS
- LGO N/A
- CHRS N/A
- Revenue
- LGO $158,899,000.00
- CHRS $308,134,000.00
- Revenue This Year
- LGO N/A
- CHRS $6.15
- Revenue Next Year
- LGO $32.23
- CHRS $15.04
- P/E Ratio
- LGO N/A
- CHRS N/A
- Revenue Growth
- LGO N/A
- CHRS 69.37
- 52 Week Low
- LGO $1.38
- CHRS $1.01
- 52 Week High
- LGO $3.08
- CHRS $4.48
- Technical
- Relative Strength Index (RSI)
- LGO 37.55
- CHRS 35.11
- Support Level
- LGO $1.59
- CHRS $1.01
- Resistance Level
- LGO $1.80
- CHRS $1.37
- Average True Range (ATR)
- LGO 0.11
- CHRS 0.11
- MACD
- LGO -0.02
- CHRS -0.02
- Stochastic Oscillator
- LGO 7.69
- CHRS 2.44
About LGO Largo Inc.
Largo Inc is committed to the production and supply of high-quality vanadium products. The Company is also focused on the advancement of renewable energy storage solutions through Largo Clean Energy and its vanadium redox flow battery technology. The Company is engaged in the mining, exploration, and development of mineral properties, predominantly in Brazil, through which it produces and supplies vanadium products VPURE Flake, VPURE+ Flake, and VPURE+ Powder. The Company has six operating segments: sales & trading wich generates key revenue, mine properties, corporate, exploration and evaluation properties, Largo Clean Energy, and Largo Physical Vanadium.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.